What does Outlook Therapeutics, Inc. do?

Jun 22 2025 06:50 PM IST
share
Share Via
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing biosimilar therapeutics, particularly monoclonal antibodies, in immunology and oncology. It has a market cap of USD 72.42 million and reported a net profit loss of USD 46 million as of March 2025.
Overview:
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing biosimilar therapeutics, particularly monoclonal antibodies, in the immunology and oncology sectors. The company operates within the Pharmaceuticals & Biotechnology industry and has a market cap of USD 72.42 Million. Financial Snapshot: Most recent Net Profit: -46 Million (Quarterly Results - Mar 2025) Market cap: USD 72.42 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.79 Return on Equity: 233.83% Price to Book: -2.23 Contact Details: Address: 4260 U.S. Route 1, MONMOUTH JUNCTION NJ : 08852 Tel: ['1 609 6193990', '1 212 9152568'] Website: http://oncobiologics.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News